Kenneth S Lloyd

US Patent:

6645935, Nov 11, 2003

Filed:

Oct 12, 2001

Appl. No.:

09/977185

Inventors:

Samuel J. Danishefsky - Englewood NJ
Victor Behar - Las Vegas NV
Kenneth O. Lloyd - New York NY

Assignee:

Sloan-Kettering Institute for Cancer Research - New York NY
The Trustees of Columbia University in the City New York - New York NY

International Classification:

A61K 3816

US Classification:

514 8, 536 41, 514 25

Abstract:

The present invention provides a method of synthesizing an allyl pentasaccharide having the structure: as well as related oligosaccharide ceramides and other glycoconjugates useful as vaccines for inducing antibodies to epithelial cancer cells in an adjuvant therapy therefor, and in a method for preventing recurrence of epithelial cancer.

US Patent:

7205142, Apr 17, 2007

Filed:

Sep 13, 2002

Appl. No.:

10/243243

Inventors:

Kenneth O. Lloyd - Bronx NY, US
Beatrice W. T. Yin - Forest Hills NY, US

Assignee:

Sloan-Kettering Institute for Cancer Research - New York NY

International Classification:

C12N 1/20

US Classification:

4352523, 435325, 435 691, 4353201, 536 231, 536 235

Abstract:

The present invention provides an isolated nucleic acid molecule comprising sequences encoding the CA125 protein or a portion thereof. This invention also provides a method to detect ovarian cancer in a subject. Furthermore, this invention provides a method for the diagnosis of a cancer which expresses CA125 by detecting CA125-expressing cells in the blood or other fluids of patients. This invention also provides a method of producing CA125 protein. This invention also provides a method of silencing CA125 protein production. Finally, this invention provides a method to treat or prevent cancer using a vaccine comprising CA125 nucleic acid or protein.

US Patent:

7550146, Jun 23, 2009

Filed:

Jul 23, 2004

Appl. No.:

10/898410

Inventors:

Samuel J. Danishefsky - Englewood NJ, US
Dalibor Sames - New York NY, US
Samuel Hintermann - Basel, CH
Peter Glunz - Yardley PA, US
Philip O. Livingston - New York NY, US
Kenneth O. Lloyd - New York NY, US
Valery Kudryashov - Brooklyn NY, US

Assignee:

Sloan-Kettering Institute For Cancer Research - New York NY

International Classification:

A61K 38/14
A61K 39/385
C07K 9/00

US Classification:

4241941, 4241851, 4242771, 514 8, 530322

Abstract:

The present invention provides novel glycoconjugates such as glycopeptides, as well as convergent methods for the synthesis thereof. An exemplary preparative approach is exemplified by the synthesis of the mucin motif commonly found on epithelial tumor cell surfaces. The present invention further provides compositions and methods of treating cancer using the glycoconjugates of the invention.

US Patent:

8603474, Dec 10, 2013

Filed:

Jan 29, 2009

Appl. No.:

12/735576

Inventors:

Gerd Ritter - New York NY, US
Beatrice Yin - New York NY, US
Anne Murray - New York NY, US
George Mark - New York NY, US
Lloyd Old - New York NY, US
Kenneth Lloyd - New York NY, US
Serhiy Souchelnytskiy - Stockholm, SE
Ivan Gout - London, GB
Valeriy Filonenko - Kviv, UA
Ramziya Kiyamova - Kviv, UA

Assignee:

Ludwig Institute for Cancer Research, Ltd. - New York NY
Institute of Molecular Biology and Genetics National Academy of Science of Ukraine - Kiev
Sloan-Kettering Institute for Cancer Research - New York NY

International Classification:

A61K 39/395
G01N 33/53
C07K 16/00
C07K 16/28
C07K 16/18

US Classification:

4241331, 4241301, 4241341, 4241391, 435 71, 5303871, 5303873, 5303879, 5303888, 5303913

Abstract:

The present disclosure relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.

US Patent:

20020006629, Jan 17, 2002

Filed:

Feb 27, 2001

Appl. No.:

09/794905

Inventors:

Samuel Danishefsky - Englewood NJ, US
Kenneth Lloyd - Bronx NY, US
Zhi-Guang Wang - Dresher PA, US
Lawrence Williams - New York NY, US

International Classification:

G01N033/574
A61K039/395
C08B037/00
C07K014/435

US Classification:

435/007230, 424/155100, 530/395000, 536/053000

Abstract:

An affinity matrix having a tumor-associated carbohydrate- or glycopeptide-based antigen bound to the matrix is provided. The affinity matrix is used to isolate, characterize, and quantitate functional antibodies or antigen-binding molecules to the tumor-associated carbohydrate- or glycopeptide-based antigen. The invention also provides a method of preparing the affinity matrix. In addition the invention provides for diagnostic and therapeutic uses of the isolated antibodies or antigen-binding molecules.

US Patent:

20030078399, Apr 24, 2003

Filed:

May 9, 2002

Appl. No.:

10/142515

Inventors:

Kenneth Lloyd - Bronx NY, US
Beatrice Yin - Forest Hills NY, US

Assignee:

Sloan-Kettering Institute for Cancer Research

International Classification:

C07H021/02
C07H021/04

US Classification:

536/023100

Abstract:

The present invention provides an isolated nucleic acid molecule comprising sequences encoding the CA125 protein or a portion thereof. This invention also provides a method to detect ovarian cancer in a subject. Furthermore, this invention provides a method for the diagnosis of a cancer which expresses CA125 by detecting CA125-expressing cells in the blood or other fluids of patients. This invention also provides a method of producing CA125 protein. Finally, this invention provides a method to treat or prevent cancer using a vaccine comprising CA125 nucleic acid or protein.

US Patent:

20040102607, May 27, 2004

Filed:

Jun 19, 2003

Appl. No.:

10/600012

Inventors:

Samuel Danishefsky - Englewood NJ, US
Dalibor Sames - New York NY, US
Samuel Hintermann - Basel, CH
Xiao Chen - Newark DE, US
Jacob Schwarz - Ann Arbor MI, US
Peter Glunz - Wilmington DE, US
Philip Livingston - New York NY, US
Scott Kuduk - Harleyville PA, US
Kenneth Lloyd - New York NY, US
Lawrence Williams - New York NY, US
Valery Kudryashov - Brooklyn NY, US

International Classification:

C07K009/00
A61K038/14

US Classification:

530/322000, 514/008000

Abstract:

The present invention provides novel -O-linked glycoconjugates such as -O-linked glycopeptides, as well as convergent methods for the synthesis thereof. The general preparative approach is exemplified by the synthesis of the mucin motif commonly found on epithelial tumor cell surfaces. The present invention further provides compositions and methods of treating cancer using the -O-linked glycoconjugates.

US Patent:

46668454, May 19, 1987

Filed:

Dec 16, 1983

Appl. No.:

6/562465

Inventors:

M. Jules Mattes - Flushing NY
John L. Lewis - New York NY
Kenneth O. Lloyd - Bronx NY
Lloyd J. Old - New York NY
Carlos Cordon-Cardo - New York NY

Assignee:

Sloan-Kettering Institute - New York NY

International Classification:

C12N 500
C12N 1500
G01N 3353
C12R 191

US Classification:

435240

Abstract:

Mouse monoclonal antibodies to several cell antigens of human ovarian, cervical and endometrial carcinomas have been produced and characterized. The distribution of the antigens was determined by mixed hemagglutination assays on 153 normal and malignant cell cultures of various types, and by immunoperoxidase staining of frozen sections of 27 normal adult and 24 fetal tissues. five monoclonal antibodies representative of five classes of mAb raised to restricted ovarian, cervical and endometrial cells were tested extensively producing mAb reactive with cancer but not normal cells. One such mAb, MF116 was readily detected in the spent culture medium of metabolically radiolabeled cells. These antibodies, reacting with relatively restricted cell surface antigens, are useful in the analysis of epithelial cell differentiation, in cancer diagnosis and therapy and in tissue typing of normal or abnormal cells.